BioXcel Therapeutics, Inc. - BTAI STOCK NEWS

BioXcel Therapeutics (BTAI) reported third quarter 2022 results, revealing a net revenue of $137,000 amidst heightened R&D expenses of $22.1 million, primarily linked to its BXCL501 clinical program. The company also posted a net loss of $41.8 million, up from $26.8 million year-on-year. Despite these losses, BioXcel is advancing its agitation-treatment market position with IGALMI™ and anticipates pivotal trial data for BXCL501 in Alzheimer’s-related agitation and bipolar disorders in 1H 2023. The firm maintains a cash balance of approximately $232.3 million as of September 30, 2022.

BioXcel Therapeutics (BTAI) has announced the release of its third quarter 2022 financial results set for November 10, 2022. The management team will hold a conference call at 8:30 AM ET to discuss these financial results and provide a business update. The financials are anticipated to cover performance metrics relevant to shareholders and the company’s AI-driven drug development in neuroscience and immuno-oncology.

BioXcel Therapeutics (Nasdaq: BTAI) has announced a Commercial Day presentation on October 18, 2022, to update on IGALMI™ (dexmedetomidine) sublingual film, a treatment for acute agitation linked to schizophrenia and bipolar disorders in adults. Key company leaders and healthcare experts will share insights on clinical applications and market strategies. IGALMI, approved by the FDA in April 2022, is administered under medical supervision due to potential serious side effects. Investors can RSVP for the event and access a live webcast via BioXcel's website.

BioXcel Therapeutics (Nasdaq: BTAI) announced that CEO Vimal Mehta and CCO Matt Wiley will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:30 a.m. ET. The discussion will focus on the company’s neuroscience and immuno-oncology programs and its AI platform for drug discovery. They will also outline the commercial launch strategy for IGALMI™ (dexmedetomidine) sublingual film, approved for treating agitation in adults with schizophrenia or bipolar disorder. A live webcast will be accessible on the company's website.

BioXcel Therapeutics (BTAI) has commercially launched IGALMI™ (dexmedetomidine) for the acute treatment of agitation in bipolar I/II disorder and schizophrenia in adults. The company plans to initiate the SERENITY III pivotal trial for at-home use of BXCL501 in 2H 2022, following a positive FDA Type B meeting. They expect top-line data from the TRANQUILITY II trial for Alzheimer's-related agitation in 1H 2023. BioXcel reported a net loss of $37.7 million for Q2 2022, with cash reserves of approximately $233.5 million, ensuring funding into 2025.

BioXcel Therapeutics (Nasdaq: BTAI) announces participation in the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 2:30 p.m. ET. CEO Vimal Mehta and CCO Matt Wiley will discuss the company's neuroscience and immuno-oncology programs, along with its AI-driven drug discovery platform. The event will also cover the commercial strategy for IGALMI™ (dexmedetomidine) sublingual film, approved for treating agitation in adults. A live webcast will be available on their website 15 minutes before the chat starts.

BioXcel Therapeutics (BTAI) announced a multi-year NIDA grant of approximately $3.3 million to fund a clinical study of BXCL501 for opioid withdrawal treatment. The grant will support a 160-patient Phase 2b trial comparing different doses of BXCL501 against placebo and Lucemyra™. This research responds to a significant health crisis, with over 142 million opioid prescriptions dispensed in the U.S. in 2020. Early trials indicated BXCL501 is well tolerated and may effectively reduce insomnia and anxiety in patients. Further funding of about $4.5 million will depend on achieving specific milestones.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) will release its second quarter 2022 financial results on August 9, 2022, before U.S. market opening. A conference call and webcast will take place at 8:30 AM ET to discuss the results and provide business updates. BioXcel utilizes artificial intelligence for drug re-innovation in neuroscience and immuno-oncology. Its product, IGALMI™, is approved for treating agitation in schizophrenia and bipolar disorders. The company is also pursuing treatments for Alzheimer's-related agitation and prostate cancer.

BioXcel Therapeutics (BTAI) announced the appointment of Michael P. Miller to its Board of Directors, effective July 1, 2022. Miller has nearly 40 years of experience in the pharmaceutical industry, previously serving as EVP, U.S. Commercial at Jazz Pharmaceuticals. His leadership is expected to enhance BioXcel's commercial capabilities as the company launches its product IGALMI, a sublingual film for treating agitation linked to Alzheimer's disease. Miller's extensive background in product launches and market access is viewed as crucial for the company's growth trajectory.